Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology-Reference-Cited by-同舟云学术

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

Published:2014-10-31 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Youssef Mohamed AFM¹,Van der Veen Fulco²,Al-Inany Hesham G¹,Mochtar Monique H³,Griesinger Georg⁴,Nagi Mohesen Mohamed⁵,Aboulfoutouh Ismail⁶,van Wely Madelon²

Affiliation:

1. Faculty of Medicine, Cairo University; Department of Obstetrics & Gynaecology; Cairo Egypt

2. Academic Medical Center, University of Amsterdam; Center for Reproductive Medicine; Meibergdreef 9 Amsterdam Netherlands 1105 AZ

3. Academic Medical Center; Department of Obstetrics and Gynaecology, Center for Reproductive Medicine; Amsterdam Netherlands

4. UKSH, Campus Lűbeck; Ratzeburger Allee 160 Lűbeck Germany 23552

5. Beni-Suef University; Department of Obstetrics & Gynaecology; Beni Suef Egypt

6. Egyptian International Fertility IVF Center (EIFC-lVF), Cairo University; Department of Obstetrics and Gynaecology; 40 Abd El Reheem Sabry St, Eldokki Mohandeseen Cairo Egypt

Publisher

Wiley

Subject

Pharmacology (medical)

Reference125 articles.

1. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates;Acevedo;Fertility and Sterility,2006

2. Serum inhibin A, VEGF and TNFa levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial;Babayof;Human Reproduction,2006

3. Non supplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment;Beckers;The Journal of Clinical Endocrinology and Metabolism,2003

4. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after co-treatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study;Engmann;Fertility and Sterility,2008

5. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization;Fauser;The Journal of Clinical Endocrinology and Metabolism,2002

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Best practice recommendations for medically assisted reproduction in patients with known cardiovascular disease or at high risk of cardiovascular disease;Human Fertility;2024-01-09

2. Effect of GnRH agonist trigger with or without low-dose hCG on reproductive outcomes for PCOS women with freeze-all strategy: a propensity score matching study;Archives of Gynecology and Obstetrics;2023-11-30

3. Retrospective Analysis of Fresh Single Blastocyst Transfer versus Two Cleavage-Stage Fresh Day-3 Embryo Transfer with High-Quality Embryos during Gonadotropin-Releasing Hormone Antagonist Cycles in High Responders;Clinical and Experimental Obstetrics & Gynecology;2023-11-21

4. Dual trigger for final oocyte maturation in expected normal responders with a high immature oocyte rate: a randomized controlled trial;Frontiers in Medicine;2023-10-05

5. In Vitro Fertilization Outcomes With a Dual Trigger in Normoresponders in Antagonist Cycles;Cureus;2023-09-20